Načítá se...
Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer mortality. CA19.9, the only tumor marker available to detect and monitor PDAC, is not sufficiently sensitive and specific to consistently differentiate early cancer from benign disease. In this study we aimed to valida...
Uloženo v:
| Vydáno v: | Clin Cancer Res |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4233184/ https://ncbi.nlm.nih.gov/pubmed/25239611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0289 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|